Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy: A Randomized Controlled Trial (SUPER): A Randomized Controlled Trial (SUPER)

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Automatic airway segmentation from computed tomography using robust and efficient 3-D convolutional neural networks

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Basal Cell Carcinoma of Prostate With MSMB-NCOA4 Fusion and a Probable Basal Cell Carcinoma In Situ: Case Report

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Forecasting lung cancer incidence, mortality, and prevalence to year 2030

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Biomarkers of subclinical atherosclerosis in patients with psoriasis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

Despite increased focus on prevention as well as improved treatment possibilities, lung cancer remains among the most frequent and deadliest cancer diagnoses worldwide. Even lung cancer patients treated with curative intent have a high risk of relapse, leading to a dismal prognosis. More knowledge on the efficacy of surveillance with both current and new technologies as well as on the impact on patient treatment, quality of life, and survival are urgently needed. We therefore designed a randomized phase 3 trial. In one arm, every other computed tomography (CT) scan is replaced by positron emission tomography/CT, the other arm is the standard follow-up scheme with CT. The standard arm is identical to the current national Danish follow-up program. The primary endpoint is to compare the number of relapses treatable with curative intent in the 2 arms. We aim to include 750 patients over a 3-year period. Additionally, we will test the feasibility of noninvasive lung cancer diagnostics and surveillance in the form of circulating tumor DNA analysis. For this purpose, blood samples are collected before treatment and at each following control. The blood samples are stored in a biobank for later analysis and will not be used for guiding patient treatment decisions.

Original languageEnglish
JournalClinical Lung Cancer
ISSN1525-7304
DOIs
Publication statusPublished - 2019

ID: 58930228